Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.
The use of lenalidomide plus rituximab may improve progression-free survival (PFS) and overall survival (OS) rates in patients with mantle cell lymphoma (MCL), according to a study presented at ASH 2017.
Patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) given a combination of venetoclax and rituximab (VR) demonstrated superior progression-free survival (PFS) over those given bendamustine plus rituximab (BR), a finding which positions VR as a potential new therapeutic option for relapsed/refractory CLL, the phase III MURANO trial shows.
Adding the immunotherapy abatacept to standard drug regimen used for preventing graft-versus-host disease (GvHD) significantly reduced, and almost eliminated, life-threatening severe acute GvHD in patients undergoing haematopoietic stem cell transplants.
Professor Robert Brodsky from Johns Hopkins University
School of Medicine, and Secretary of ASH, details findings of four of the
late-breaking trials: Hokusai VTE-Cancer (dalteparin), Murano (venetoclax),
Alcyone (daratumumab), and Hercules (caplacizumab) trials.
Professor Gary Raskob from the College of Public Health,
University of Oklahoma, Oklahoma City, US speaks about the efficacy and safety
of dalteparin vs low-molecular-weight heparin/edoxaban for venous
thromboembolism in patients with cancer.
Adolescent and young adult (AYA) patients treated for acute lymphoblastic leukaemia (ALL) were more likely to have an increased rate of toxicities in every organ system compared with children, according to a study presented at ASH 2017.
Rituximab maintenance following first-line immunotherapy with R-CHOP* is highly effective for mantle cell lymphoma (MCL), with prolonged progression-free survival (PFS) and overall survival (OS) rates compared with interferon-alpha maintenance, according to the long-term follow-up results of the European MCL Elderly trial presented at ASH 2017.
The noninferiority of edoxaban compared with dalteparin in preventing recurrent venous thromboembolism (VTE) and major bleeding in patients with cancer highlights edoxaban as a potential alternative to low molecular weight heparin (LMWH) in this group of patients, suggests results of the Hokusai VTE-Cancer Study presented at ASH 2017.
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.